

Interests Register

Lung cancer Advisory Committee

Publication Date: 21/01/2019

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Gary McVeigh	Committee Chair	None	N/A	N/A	N/A	N/A	No action
Douglas West From February 2018	Committee Vice-Chair Thoracic Surgeon	Direct financial	Fees, and travel expenses received from Johnson and Johnson for acting as faculty on a number of sessions for spinal surgeons (ongoing).	Mar 2014	Dec 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.
Douglas West From February 2018 Vice-chair from April 2018	Committee Vice-Chair Thoracic Surgeon	Direct financial	Fees, and travel/accommodation expenses received from Medtronic, for teaching surgical teams how to perform thoracoscopic (VATS) lobectomy operations.	Apr 2017	Dec 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.

<p>Douglas West</p> <p>From February 2018</p> <p>Vice-chair from April 2018</p>	<p>Committee Vice-Chair</p> <p>Thoracic Surgeon</p>	<p>Direct Financial</p>	<p>Fee received from Astra Zeneca. For talks on stage 3 lung cancer, Clinical Expert Group on Immunotherapy for non-small lung cancer</p>	<p>Nov 2017</p>	<p>Dec 2017</p>	<p>Declare and participate</p> <p>Not specific to any topic covered in the scope of the guideline.</p>
<p>Douglas West</p> <p>From February 2018</p> <p>Vice-chair from April 2018</p>	<p>Committee Vice-Chair</p> <p>Thoracic Surgeon</p>	<p>Direct non-financial</p>	<p>Part of a panel for Public Health England to support the writing of a report; Perspectives in Lung Cancer Care (organisation of lung cancer services and identifying areas of best practice in Europe that could be applied to the NHS.). Bristol Myers Squibb will pay travel expenses for the 3 meetings</p>	<p>Apr 2018</p>	<p>Apr 2018</p>	<p>Declare and participate</p> <p>Not specific, will not focus on specific treatments or drugs covered in the lung cancer guideline update.</p>
<p>Shahzeena Aslam</p>	<p>Committee member</p> <p>Clinical Oncologist</p>	<p>Direct financial (conference fee only)</p>	<p>Attended British thoracic oncology group conference in Dublin from 24th -26th January 2018. Pfizer have agreed to pay conference fee</p>	<p>Jan 2018</p>	<p>Feb 2018</p>	<p>Declare and participate</p>

Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial (travel, accommodation and conference fee)	Attended Prostate cancer summit in London, 23rd and 24th Feb 2018 Sponsored by Janssen for travel, accommodation and conference fee.	Feb 2018	Mar 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Shahzeena Aslam	Committee member Clinical Oncologist	Direct non-financial	Attended a meeting sponsored by BMS in Cambridge exploring clinical cases of lung cancer treated with nivolumab	Mar 2018	Apr 2018		Declare and participate
Shahzeena Aslam	Committee member Clinical Oncologist	Direct non-financial	Attended a British Thoracic Oncology Group neuroendocrine/small cell lung cancer essential update meeting 18/04/18. Free event.	Apr 2018	May 2018		Declare and participate
Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial (travel and subsistence only)	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and	Jun 2018	Jun 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.

			accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.				
Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial	Paid work for IQVIA clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be “real world” data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs.	Jun 2018	Jun 2018		Declare and participate The work is provision of generic real world data with no direct link to the scope of the guideline.
Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial (travel, accommodation, subsistence only)	Attend a bladder cancer forum 28th June 2018, sponsored by Roche. Travel, accommodation and subsistence.	Jul 2018	Jul 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.

Elaine Borg	Committee member Pathologist	Direct financial	Honorarium received for lecture at EBUS masterclass. Event hosted by UCLH and sponsored by AstraZeneca	Oct 2017	Dec 2017		Related to RQ1.2 & RQ1.2 (GComm2, 4.12.17) declaration not made until after the committee meeting. Exclude from any future recommendation making for RQ1.2 & RQ1.2
Elaine Borg	Committee member Pathologist	Direct financial	Honorarium received for lecture at EBUS masterclass June 2018	Jun 2018	May 18		Related to RQ1.2 & RQ1.2 Exclude from any future recommendation making for RQ1.2 & RQ1.2
Lynn Campbell	Committee member Medical Oncologist	Direct financial	Payment from Pfizer for delivering a presentation: 'Presentation of first-line Crizotinib data'.	Feb 2017	July 2017		Declare and participate Not specific to any topic covered in the scope of the guideline. Crizotinib is one of the cancer TA drugs which is in the chemotherapy algorithm
Lynn Campbell	Committee member Medical Oncologist	Direct non-financial	Attended an evening meeting sponsored by Roche about immunotherapy on the 3 rd May 2018. General info about immunotherapy	May 2018	May 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.

			drugs in practice. Refreshments provided				
Lynn Campbell	Committee member Medical Oncologist	Direct financial (travel and subsistence only)	Attendance at Oncology Forum meeting, Liverpool, June 2018. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.	Jun 2018	Jun 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Steve Connor From May 2018	Committee member Neuroradiologist	Direct Financial	Receives payment for work in private hospitals. Paid directly. 95% of private practice fees from HCA insurance. 1/6 of the working week is spent in private practice. Private practice is for general neuroradiology	2002	Apr 2018		Declare and participate Not specific to any topic covered in the scope of the guideline, private work does not relate to lung cancer, but rather general neuroradiology

			imaging and none in relation to lung cancer.				
Steve Connor From May 2018	Committee member Neuroradiologist	Direct non-financial	Research collaborations with head and neck oncology groups, in regards to head and neck cancer treatment. Not related to the scope of this guideline update.	2012	Apr 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Sujal Desai	Committee member Radiologist	Direct non-financial	DMC Radiology Reporting Ltd partner. The company does not provide any imaging services. Provides outsourcing teleradiology for the NHS and private sector. No financial remuneration received.	Aug 2005	Oct 2017		Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.
Sujal Desai	Committee member Radiologist	Direct financial	Taught courses/workshops (not lung cancer), in Hong Kong and Beijing for IDKD. The topics were; interstitial lung diseases, airways diseases and mediastinal and hilar disorders. Flight and	2017	Oct 2017		Declare and participate Not specific to any topic covered in the scope of the guideline. IDKD is the course provider therefore payment is non commercial

			accommodation paid, honorarium received.				
Sujal Desai	Committee member Radiologist	Direct financial	Attended a meeting by Pfizer, for the launch of their antifungal drug Isavuconazole. Paid an honorarium and travel costs.	Nov 2017	Dec 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.
Sujal Desai	Committee member Radiologist	Direct non-financial	Speaking at a European Congress of Radiology in Vienna. Conference on smoking related interstitial lung diseases (not lung cancer related), Conference fee waived, travel and accommodation.	Mar 2018	Feb 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Sujal Desai	Committee member Radiologist	Direct financial	Run an educational course for Boehringer Ingelheim, on interstitial lung diseases. Honorarium and travel costs will be paid	June 18	June 18		Declare and participate Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Direct non-financial professional and personal	Medical Director of Roy Castle Lung Cancer Foundation. The organisation receives grants from	1998	Jul 2017		Declare and participate

			pharmaceutical companies as part of its funding. Does not exceed 6% of their income				
Jesme Fox	Committee member Lay member	Indirect financial	Presented at a number of conferences and participated in several advisory boards, organised by pharmaceutical companies. Honorarium paid to employer.	1998	Jul 2017		Declare and participate
Jesme Fox	Committee member Lay member	Indirect financial	Attended an Advisory Board meeting for Takeda. Honorarium paid to employer. Travel and accommodation paid. Donation given to employer	Jan 2018	Jan 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Non-financial professional and personal	Paper by O'Dowd was discussed at previous meeting/GCom2. Charity employer, Roy Castle Lung Cancer Foundation funded Dr O'Dowd's 3 year Clinical Research Fellowship post at Nottingham University (2013 to 2015). The research paper	2013	Feb 2018		Declare and participate No involvement in the production of the study

			discussed was one of several she undertook and published during this time.				
Jesme Fox	Committee member Lay member	Direct non-financial	Participated in a short Advisory Board teleconference 08.04.18, with Boehringer Ingelheim. No honorarium or expenses were paid. The topics discussed were not relevant to Committee discussions (non-medical interventions).	Apr 2018	Apr 2018		Declare and participate
Jesme Fox	Committee member Lay member	Direct financial (travel and subsistence)	31st May, attended a Global Oncology Advocacy Leaders Meeting in Chicago. Travel and accommodation expenses paid by Bristol-Myers Squibb. The topics discussed general cancer issues, not relevant to lung cancer guideline.	May 2018	Jun 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Indirect financial (Honorarium donated to employer)	July 9th/10th 2018. July 9th/10th 2018, attended an Advisory Board meeting for Pfizer. Travel	Jul 2018	Jul 2018		Declare and participate

			and accommodation paid by Pfizer. Honorarium donated to employer. Topic of discussion, patients and clinical trials. Not related to the scope of the guideline update				Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Indirect financial (Honorarium donated to employer)	July 17th 2018, attended an Advisory Board meeting for Takeda. Travel paid by Takeda. Honorarium donated to employer. Topic of discussion the patient journey. Not related to the scope of the guideline update.	Jul 2018	Jul 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Tom Haswell	Committee member Lay member	Direct financial	National Cancer Research Institute (NCRI) – Lung studies group. Attend 2 meetings a year, receives an honorarium.		Oct 2017		Declare and participate–non-commercial activity.
Tom Haswell	Committee member Lay member	Direct financial (travel and subsistence)	Steering Committee member of the British Thoracic Oncology Group. Attended the annual conference where British Thoracic	2014	Feb 2018		Declare and participate

			Oncology Group paid travel and accommodation.				
Sue Maughn	Committee member Commissioner	Direct financial (travel and subsistence)	United Kingdom - lung cancer coalition - speaker on sustainability and transformation partnerships in the commissioning of best practice lung cancer services	Apr 2018	Mar 2018		Declare and participate
Andrea McIver	Committee member Nurse	Direct financial (travel and subsistence)	Attended the National lung nurse forum for nurses (NLCFN) workshop 14th & 15th May. Accommodation and refreshments provided by NLCFN.	May 2018	May 2018	N/A	Declare and participate Not specific to any topic covered in the scope of the guideline
Neal Navani	Committee member Respiratory Physician	Direct financial	Honorarium received for lecture at EBUS masterclass in October 2017. Event hosted by UCLH and sponsored by AstraZeneca.	Oct 2017	Apr 2017		Partial exclusion, excluded from making recommendations. Related to RQ 1.1 & RQ 1.2 (GComm2, and GComm8).
Neal Navani	Committee member Respiratory Physician	Direct financial (travel and subsistence)	Chairing "global advisory board" March 2017, for Astra Zeneca. Travel arranged, no honorarium received.	Mar 2017	Apr 2017		No action other than the process of open declaration

Neal Navani	Committee member Respiratory Physician	Direct financial (travel and subsistence)	Travel and conference registration from MSD to attend World Lung Cancer conference Dec 2016	Dec 2016	Apr 2017		No action other than the process of open declaration
Neal Navani	Committee member Respiratory Physician	Direct financial	Investigator on Lung boost trail (published 2015). Study funded by MRC and included salary payment for 3 years.	2008	Oct 2017		Partial exclusion, excluded from making recommendations. Paper to be included as evidence for RQ 1.1 & RQ 1.2 (GComm2, and GComm8).
Neal Navani	Committee member Respiratory Physician	Direct financial	Private practice, same scope as NHS work (except, do not prescribe any treatments). Set up as a limited company, income from private practice, is managed via the company. Private income mainly via insurers, on a fee basis. Includes carrying out EBUS procedures (approx 10 per week on	Apr 2017 for company	Dec 2017		Partial exclusion, excluded from making recommendations. RQ 1.1 & RQ 1.2 (GComm2, and GComm8) Only procedure related to the guideline carried out in private practice is EBUS

			the NHS and 1 per week privately				
Neal Navani	Committee member Respiratory Physician	Indirect financial	Attended an advisory board (Lung cancer related, but not on any of the topics being covered in the guideline): Honoraria will be paid into the employer's research account.		Dec 2017		Declare and participate
Neal Navani	Committee member Respiratory Physician	Indirect financial	Attended optimising outcomes in lung cancer meeting in Rome, accommodation & travel paid for by AZ. Honorarium paid to research account	Nov 2017	Dec 2017		Declare and participate
Neal Navani	Committee member Respiratory Physician	Indirect financial	Attending in March 2018, EBUS Re-biopsy class Cardiff. Honorarium paid to employer. Astra Zeneca to pay expenses, and travel	Mar 2018	Dec 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.
Neal Navani	Committee member Respiratory Physician	Direct financial, (travel, accommodation, conference fees and subsistence)	Speaking at event in, Slovenia, at the European Society of Thoracic surgery (ESTS), on the cost-effectiveness of lung cancer screening.	May 2018	Dec 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.

			ESTS paying conference registration fee, expenses and accommodation.				
Neal Navani	Committee member Respiratory Physician	Direct financial (travel and subsistence)	Attended European Endoscopy Forum meeting in Hamburg, accommodation & travel paid for by Olympus.		Dec 2017		Declare and participate
Neal Navani	Committee member Respiratory Physician	Direct financial (travel and subsistence),	May 2018 Presented at the American Thoracic Society Conference; 'Interventional Pulmonology' in San Diego. Travel and accommodation paid by Oncimmune Ltd. No payment received.	May 2018	May 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Marco Scarci Resigned October 2017	Committee member Thoracic Surgeon	None	N/A	N/A	N/A		No action
Michael Snee Resigned October 2017	Committee member Clinical Oncologist	Direct financial (travel and subsistence)	Attended world lung cancer conference, Vienna – received	Dec 2016	Mar 2017		Declare and participate

			hospitality from Astra Zeneca (dinner)				
Michael Snee Resigned October 2017	Committee member Clinical Oncologist	Direct financial	Paid work for (Quintiles IMS) clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be “real world” data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs.		Jul 2017		Declare and participate The work is provision of generic real world data with no direct link to the scope of the guideline.
David Waller From December 2017 Resigned January 2018	Committee member Thoracic Surgeon	None	N/A	N/A	N/A		No action
Rhiannon Walters-Davies	Committee member Pharmacist	Direct financial (travel and subsistence)	Travel and conference paid by Boehringer, for American Society of	Jun 2017	Oct 2017		Declare and participate

			Clinical Oncology conference				
Rhiannon Walters-Davies	Committee member Pharmacist	Direct financial (travel and subsistence)	Travel and conference paid by Pierre Fabre, for British Thoracic Oncology Group conference	Jan 2017	Oct 2017		Declare and participate
Rhiannon Walters-Davies	Committee member Pharmacist	Direct financial (travel and subsistence)	Travel and conference paid by Ipsen, for British Oncology Pharmacy Association conference	Oct 2017	Oct 2017		Declare and participate
Rhiannon Walters-Davies	Committee member Pharmacist	Indirect financial	5th Prostate Forum Wales- 11th December, education event sponsored by Astellas. Honorarium paid to pharmacy education endowment fund at Velindre (not the budget holder for the fund).	Dec 2017	Jan 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Rhiannon Walters-Davies	Committee member Pharmacist	Indirect financial	Attended an AZ education event Osimertinib Audit Honorarium paid to education budget (not the budget holder)		Feb 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.

Rhiannon Walters-Davies	Committee member Pharmacist	Indirect financial	Attended a Roche education event, on Pharmacist prescribing immunotherapies Honorarium paid to education budget (not the budget holder). Travel and accommodation paid.		Feb 2018		Declare and participate Not specific to any topic covered in the scope of the guideline.
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non-financial personal and professional	Written an article on advances in lung cancer, (Systemic anti-cancer therapy pathway) for Clinical pharmacist journal, published June 2018	Feb 2018 Updated Jul 2018	Feb 2018		Declare and participate
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non-financial (Attended a meeting on how to horizon forecast for upcoming drugs (all drugs not yet approved). The meeting was held in March 2018 supported by the Association of the British Pharmaceutical Industry.	Mar 18	May 18		Declare and participate Not specific to any topic covered in the scope of the guideline.
Rhiannon Walters-Davies	Committee member Pharmacist	Indirect financial	Attend an advisory board, for Astra Zeneca, 5th July 2018, on Durvalumab.	Jun 18	Jul 18		Declare and participate Not specific to any topic covered in the scope of the guideline.

			Accommodation, travel and expenses paid. Honorarium paid to education fund. The topics discussed, were not relevant to lung cancer guideline.				
Rhiannon Walters-Davies	Committee member Pharmacist	Indirect financial	Attend an internal meeting (educational) for Boehringer, 26th June 2018, on Afatanib. Honorarium paid to education fund. Accommodation, travel and expenses paid.	Jun 18	Jun 18		Declare and participate
Rhiannon Walters-Davies	Committee member Pharmacist	Direct financial (travel and subsistence)	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological	Jun 18	Jun 18		Declare and participate Not specific to any topic covered in the scope of the guideline

			companies, predominantly Novartis, Health care at Home.				
Nigel Westwood	Committee member Lay member	None	N/A	N/A	N/A		No action
Clifford Wyn Jones	Committee member GP	Direct financial	Assessor for Palliative (paid) Medicine Diploma – Cardiff University	Jan 2017	Jun 2017		Declare and participate Not specific to any topic covered in the scope of the guideline.
Clifford Wyn Jones	Committee member GP	Direct financial	Framework for Cancer, National GP lead (paid role). An NHS post funded by Macmillan Cancer Support	Jul 2015	Jun 2017		Declare and participate Non-commercial

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.